Mr. Michael McFadden reports

ALPHA COGNITION ANNOUNCES FILING OF S-1 RESALE REGISTRATION STATEMENT

Alpha Cognition Inc. has filed a resale registration statement on Form S-1 with the Securities and Exchange Commission (SEC) to register the resale of common shares issued pursuant to the company's private placement transactions, which closed on Aug. 31, Oct. 16, Nov. 8 and Dec. 22, 2023, and Jan. 19, 2024. The registration statement was filed pursuant to registration rights granted by the company in connection with the private placements to the selling shareholders named in the registration statement.

The registration statement filed with the SEC has not yet been declared effective, and the securities may not be sold, and offers to buy may not be accepted, until the registration statement becomes effective. The registration statement is subject to amendment and completion. Copies of the registration statement and the preliminary prospectus contained therein may be obtained from the company by request made to Alpha Cognition care/of 1200, 750 West Pender St., Vancouver, B.C., V6C 2T8, or by e-mail at info@alphacognition.com, or by visiting EDGAR.

If and when the registration statement is brought effective, the company will become a reporting issuer under Section 15(d) of the United States Securities Exchange Act of 1934, as amended, and will file reports under the Exchange Act with the United States Securities and Exchange Commission. Such report will be available at the SEC website and on the company's website.

About Alpha Cognition Inc.

Alpha Cognition is a precommercial, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease following the recent new drug application submission and acceptance by the Food and Drug Administration.

ALPHA-1062 is a patented new innovative product being developed as a next-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is in development in combination with memantine to treat moderate to severe Alzheimer's disease, in development with a sublingual formulation for patients suffering from dysphagia, and is being out-licensed to study an intranasal formulation for cognitive impairment with mTBI (mild traumatic brain injury, otherwise known as concussion).

We seek Safe Harbor.